| Recruiting | Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies Hematolymphoid Malignancies | EARLY_Phase 1 | 2025-12-12 |
| Recruiting | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | 2025-12-03 |
| Recruiting | Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymph Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult | EARLY_Phase 1 | 2025-09-25 |
| Recruiting | PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | Phase 2 | 2025-09-25 |
| Not Yet Recruiting | Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection. Systemic Sclerosis (SSc) | EARLY_Phase 1 | 2025-06-01 |
| Not Yet Recruiting | Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection Rheumatoid Arthritis (RA) | EARLY_Phase 1 | 2025-06-01 |
| Not Yet Recruiting | Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome | EARLY_Phase 1 | 2025-05-18 |
| Not Yet Recruiting | Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | N/A | 2025-03-18 |
| Not Yet Recruiting | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis | EARLY_Phase 1 | 2024-05-14 |
| Recruiting | Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis | N/A | 2024-04-02 |
| Recruiting | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma | N/A | 2024-04-01 |
| Recruiting | UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. CD19-positive Relapsed or Refractory B-cell Malignancies | EARLY_Phase 1 | 2023-10-01 |
| Recruiting | TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma B7-H3-positive Relapsed/ Refractory Neuroblastoma | Phase 1 | 2022-12-30 |
| Unknown | Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia | EARLY_Phase 1 | 2022-12-27 |
| Unknown | UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | 2022-09-26 |
| Unknown | TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukem FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia | EARLY_Phase 1 | 2022-06-09 |
| Unknown | PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malign CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies | Phase 1 | 2021-12-01 |
| Unknown | TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia CAR, Acute Myeloid Leukemia | N/A | 2021-07-01 |
| Unknown | A Clinical Trial of TAA06 Injection in Advanced Solid Tumors Malignant Melanoma, Lung Cancer, or Colorectal Cancer | Phase 1 | 2021-06-01 |
| Unknown | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 P Osteosarcoma, Neuroblastoma, Gastric Cancer | EARLY_Phase 1 | 2021-05-14 |
| Unknown | CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia T-ALL | N/A | 2021-03-04 |
| Unknown | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Labe T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific | Phase 1 | 2020-11-24 |
| Unknown | CAR-T for r/r Malignant Tumors in Children CAR-T, Child, Only, Malignant Tumor | EARLY_Phase 1 | 2020-09-27 |
| Unknown | CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors CAR, Malignant Tumors | EARLY_Phase 1 | 2020-06-03 |
| Unknown | γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse Leukemia, B-cell | EARLY_Phase 1 | 2020-05-01 |
| Unknown | TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia CAR, Acute Myeloid Leukemia | N/A | 2019-12-09 |
| Unknown | CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors CAR, Solid Tumor | N/A | 2019-09-01 |
| Unknown | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic L T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia | Phase 1 | 2019-08-25 |
| Unknown | CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma Non Hodgkin Lymphoma | N/A | 2019-05-31 |
| Unknown | CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malign CAR | EARLY_Phase 1 | 2019-04-19 |
| Unknown | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma Multiple Myeloma | EARLY_Phase 1 | 2019-03-08 |
| Unknown | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Primary Cutaneous Follicle Centre Lymphoma | Phase 1 | 2018-12-01 |
| Completed | Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor Multiple Myeloma | EARLY_Phase 1 | 2018-10-11 |
| Unknown | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refr B Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma | EARLY_Phase 1 | 2018-01-09 |
| Unknown | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With Maturation | Phase 1 / Phase 2 | 2016-10-01 |
| Unknown | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma | Phase 1 / Phase 2 | 2016-10-01 |
| Unknown | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia a Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma | Phase 1 / Phase 2 | 2016-09-01 |
| Unknown | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymp Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma | Phase 1 / Phase 2 | 2016-07-01 |
| Unknown | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | 2016-07-01 |
| Unknown | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | 2016-03-01 |
| Unknown | CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Malignant Glioma of Brain, Colorectal Carcinoma, Gastric Carcinoma | Phase 1 / Phase 2 | 2015-11-01 |
| Unknown | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | 2015-10-01 |